As of publication, Ozempic and Mounjaro are not approved by the FDA for weight loss or weight management (though clinicians sometimes prescribe these drugs for such off-label uses)
In March 2024, Viking Therapeutics announced positive results from the company's Phase I multiple ascending dose (MAD) clinical trial of an oral tablet formulation of VK2735 , a dual agonist of the glucagon-like peptide 1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) receptors, in development for the potential treatment of metabolic disorders such as obesity
A patient with UnitedHealthcare Illinois coverage may face different criteria than one with UnitedHealthcare California
Lastly, insurance coverage and cost can also be determining factors, as some plans may favor one medication over the other
For men, GLP-1 agonist treatment improves fertility, regardless of its effects on weight, she adds
Ongoing research continues to refine our understanding of these medications